Scott Rauch 2017_0.jpg

President and Psychiatrist in Chief, McLean Hospital
Chair of Psychiatry and Mental Health, Partners Health Care System
Professor of Psychiatry, Harvard Medical School


Dr. Rauch’s principal research interests relate to neuroimaging and the neurobiology of anxiety disorders. He has been a leader in delineating the neurocircuitry of anxiety disorders, as well as a pioneer in developing surgical and device-based treatments for obsessive-compulsive and mood disorders. He has won numerous honors for his contributions to psychiatric neuroscience.

LOGO_Clinical_Fellow_ADAA-01.jpgDr. Rauch joined ADAA in 1999.

Why am I an ADAA member?

ADAA has always been an organization that best resonates with my interests, as I am a career clinician-scientist-educator with a focus on anxiety and depression. I was first drawn to ADAA because of the annual meeting, which brings together outstanding researchers and teachers with active clinical providers who represent the diversity of venues where patients and families receive their care. The annual meeting is now better than ever with something for everyone, at highest quality. I especially value the way our community brings together varied experience, expertise and perspectives to advance the field, including via mentoring the next generation and public education. In addition to the meeting, ADAA’s journal, web-presence, and other elements have evolved toward ever greater positive impact. There is no other organization that so effectively promotes this type of integration and synergy focused specifically on depression and anxiety disorders.

What do I value about the ADAA mission and how does my work fit into the ADAA mission?

As anxiety and depression represent among the most common, potentially disabling, and treatable conditions, nationally and globally, the mission to advance care, research and education in this domain is profoundly compelling. I especially appreciate the fundamental mission commitment to improving the lives of those with depression and anxiety disorders, the tri-partite approach valuing care, research and education, and the explicit focus on multi-disciplinary, evidence-based practices, and an emphasis on accelerating translation. Born out of an academic medicine environment, the culture of ADAA has always felt like a perfect fit for me. Currently, I have leadership responsibilities at McLean Hospital, Harvard Medical School, and Partners Healthcare, which have missions well aligned with ADAA across clinical service, research and education in the realm of behavioral and mental health.      

What is the thing that I think is most exciting/interesting about what is currently happening in my lab or workplace?

At McLean Hospital our Chief Scientific Officer, Dr. Kerry Ressler, is leading a newly launched and endowed trauma initiative to advance translational science, including a growing investment in epigenetic and other translational research as well as evidence –based practice in our specialty trauma-units and trauma-informed care across our services. At Partners Healthcare and in my lab, I am especially excited about projects we have ongoing to leverage technology to accelerate translation and enhance access to care. This includes McLean Hospital’s recently launched Institute for Technology in Psychiatry, seeking to leverage data from mobile and wearable devices, as well as enhance care beyond our campuses through teleconsultation and web-based/online therapies (eg, internet CBT).